Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2020-03-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific employees, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the regulator that does not fit into the other specialized categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2020-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is titled '감사보고서 제출' (Submission of Audit Report) and provides a summary table of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the fiscal year. It is a standard regulatory filing in Korea (DART system) used to announce that the audit report has been submitted to the regulator. Since it is a summary announcement of the audit results rather than the full, multi-page audit report document itself, it falls under the category of a Report Publication Announcement. FY 2019
2020-03-19 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Celltrion Pharm. It includes the agenda for the meeting, details on electronic voting, and, crucially, the 'Management Reference Materials' (경영참고사항) which contain the financial statements (balance sheets, income statements, etc.) to be approved at the meeting. While it contains financial data, it is not an Annual Report (10-K) but rather a proxy-related document for the AGM. According to the provided categories, documents detailing information for shareholders to vote on at an AGM, including financial statements for approval, are classified as Proxy Solicitation & Information Statement (PSI).
2020-03-19 Korean
[기재정정]의결권대리행사권유참고서류
Audit Report / Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) filed by Celltrion Pharm, which amends previously submitted information regarding the Annual General Meeting (AGM) materials. Specifically, it provides corrected financial statements (balance sheets, cash flow statements) that were part of the 'Reference Documents' (참고서류) for the 20th Annual General Meeting. Since this document is an amendment to the materials provided for an AGM, it falls under the AGM-R category. FY 2019
2020-03-19 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Celltrion Pharm. It contains the agenda for the 20th Annual General Meeting, including reports on internal accounting, audit reports, financial statement approval, and director/auditor appointments. It also includes detailed management reference materials (경영참고사항) such as financial statements (balance sheet, income statement, cash flow) and board activity reports. This document is a formal proxy statement/notice sent to shareholders to inform them of the meeting and provide necessary information for voting, which fits the 'Proxy Solicitation & Information Statement' category.
2020-02-28 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a 'Reference Document' (참고서류) filed by Celltrion Pharm in preparation for its 20th Annual General Meeting (AGM). It contains proxy solicitation information, details on the meeting date and location, and financial statements (consolidated and separate) for the fiscal year 2019. In the context of Korean regulatory filings (DART), this type of document is a 'Proxy Solicitation & Information Statement' (PSI) provided to shareholders to inform them of the agenda and financial status prior to the AGM.
2020-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.